Objectives-To examine whether age at entry, history of cigarette smoking, exposure to non-tobacco lung carcinogens, or previous pulmonary illnesses were confounders or eVect modifiers of the relation between screening and lung cancer mortality in the Mayo Lung Project. Setting-The Mayo Lung Project was a randomised, controlled, clinical trial conducted between 1971 and 1986 in 9211 male smokers over the age of 45 in Minnesota (USA). The group screened received chest x ray examination and sputum cytology every four months for six years. The unscreened group were recommended to obtain usual care (annual chest x ray examination and sputum cytology). After follow up, lung cancer mortality was similar in both groups. Methods-Proportional hazard models were used to analyse data. A variable was considered a confounder if its inclusion in a model changed the rate ratio for screening by more than 15%; a variable was considered an eVect modifier if its stratumspecific rate ratio for screening diVered by a factor of two. Results-None of the four aforementioned variables changed the rate ratio associated with screening (1.07) by more than 2%. The eVect of screening may have diVered by years smoked (rate ratio for smoking fewer than 30 years 2.4; rate ratio for smoking 30 or more years 1.0), though we suspect that this result occurred by chance. Conclusion-Adjustment for or stratification by four established lung cancer risk factors did not alter the original findings of the Mayo Lung Project. (J Med Screen 1999;6:47-49) 
In 1971 the Mayo Lung Project, a randomised, controlled clinical trial conducted in 9211 male smokers over the age of 45, was started to assess the ability of a screening regimen to reduce lung cancer mortality. 1 Subjects randomly allocated to the screening group received chest x ray examination and sputum cytology every four months for six years; those randomly allocated to the usual care group received only a recommendation to obtain the same tests annually. At the end of the follow up period (June 1983), subjects in the screened group and those in the unscreened group had similar lung cancer mortality. 1 Controversy still surrounds the results of the Mayo Lung Project. 2 Proponents of lung cancer screening suggest that inadequate statistical power and contamination of the unscreened group were at least in part to blame for the null results. 3 It recently was suggested that the screened and unscreened groups might have diVerent distribution of factors that could have influenced incidence and mortality. 2 Although extreme population heterogeneity is unlikely in randomised studies, a minor, non-statistically significant imbalance can influence the outcome, even if the factor out of balance is not strongly related to the outcome. 4 The usefulness of screening may also diVer owing to the level of a particular risk, or prognostic factor. One possible factor that might aVect results is age, which influences the eYcacy of other screening procedures-for example, mammography. 5 We reanalysed the Mayo Lung Project data to assess whether adjustment for age at entry, smoking history, exposure to non-tobacco lung carcinogens, or past pulmonary illnesses influenced the outcome of the trial. In addition, we explored stratum-specific results of these four characteristics.
Methods

DESCRIPTION OF THE MLP
The design, conduct, and results of the Mayo Lung Project have been discussed extensively. 1 6 7 Briefly, the Mayo Lung Project, a randomised, controlled clinical trial instituted by the National Cancer Institute, was designed to assess whether a regimen of chest x ray examination and sputum cytology would reduce lung cancer mortality. In 1971, male, heavy-smoking (a pack a day or more) Mayo Clinic outpatients aged 45 or older were oVered procedures (including chest x ray examination and sputum cytology) to determine if they had lung cancer (none was suspected of having lung cancer). A total of 10 933 men were screened. The 9211 subjects who were negative for lung cancer, had a life expectancy of at least five years, and a respiratory reserve considered adequate for the patient to undergo lobectomy, if necessary, were then considered eligible to take part in the remainder of the trial. They were randomly allocated to one of two groups: a screening group who received chest x ray examination and three-day pooled sputum cytology every four months for six years (n=4618); a control group who were advised to obtain an annual x ray examination and sputum cytology on their own (n=4593 the Mayo Clinic's standard lung cancer screening recommendations at that time. All participants were asked to complete baseline and annual questionnaires. The baseline questionnaire asked for details of smoking habits, past exposure to non-tobacco lung cancer risk factors, and history of pulmonary illnesses. After the six years of screening, participants were followed up for between one and five and a half years. The study was completed on 1 July 1983, with only 26 patients lost to follow up. In the screened group 122 confirmed lung cancer deaths and 815 deaths due to other causes had occurred; in the usual care group 115 confirmed lung cancer deaths and 821 deaths due to other causes had occurred. The lung cancer mortality rate for the screened group was 3.2/1000 person-years, and for the group receiving usual care, 3.0/1000 person-years, indicating no benefit of screening.
DATA ANALYSIS
We examined baseline data on age at randomisation, cigarette smoking habits (years smoked, amount usually smoked), non-tobacco lung carcinogens (air pollution, arsenic, asbestos, nickel or chromium, and radioactive material), and previous pulmonary illnesses (emphysema, tuberculosis, and bronchitis or pneumonia). Pack-years of cigarette smoking were calculated by multiplying years smoked by amount usually smoked a day and dividing that quantity by 20. Categorised versions of continuous variables were created; continuous measures also were used when appropriate. We examined the individual pulmonary illnesses and non-tobacco carcinogens singly; we also created dichotomous variables indicating a history of any pulmonary illness (versus no previous pulmonary illness) and exposure to any non-tobacco carcinogen (versus no exposure to non-tobacco carcinogens). A variable that further specified exposure to any non-tobacco carcinogen as the number of such exposures (1, 2 or more) was also derived.
Using the PHREG procedure of the software package SAS, 8 we applied proportional hazard models to generate a ratio of lung cancer mortality rates (for the entire course of the study including follow up to June 1983) in each group (the rate equalled the number of lung cancer deaths divided by total personyears). The rate for the screened group was the numerator in the rate ratio, while the rate for the unscreened arm was the denominator. The validity of the proportional hazards assumption was tested by including an interaction term consisting of time and the exposure of interest. If the p value for the associated was 0.05 or less, the proportional hazards assumption was said not to hold.
We used a model based approach to examine confounding and eVect modification. To assess confounding, we first fitted a model including a term for the study group only. A series of adjusted models were then fitted, including each potential confounder singly. For potential confounders that were parameterised in a number of ways, separate models were fitted using each parameterisation. If the rate ratio associated with screening changed by 15% or more after inclusion of a variable, relative to the unadjusted rate ratio, the added variable was considered to be a confounder. A final model was fitted with the screening group variable and all four potential confounders. For the final model we used the age and cigarette smoking parameterisations whose inclusion in bivariate analyses changed the unadjusted screening rate ratio the most. In the instance of all parameterisations aVecting the rate ratio equally, we chose the most "parsimonious parameterisation"-that is, the coding that used the fewest parameters. Also for similar reasons, we used the "none/any" parameterisation for exposure to non-tobacco carcinogens and previous pulmonary illnesses. To assess eVect modification we used stratum-specific models. EVect modification was said to exist if any two stratum-specific rate ratios diVered by a factor of two.
Results
Subjects who were randomly allocated to the screening group had similar age at randomisation, cigarette smoking patterns, exposure to *199 people in the screened group and 204 people in the usual care group had two or more exposures; therefore, the sum of the exposures is greater than the number of people ever exposed. †83 people in the screened arm and 86 people in the usual care arm had a positive history of two or more pulmonary illnesses; therefore the sum of the illnesses is greater than the number of people with a positive history.
non-tobacco lung carcinogens, and previous lung illnesses as those who were randomly allocated to the usual care group (table 1) . With inclusion of the four potential confounders, either singly or as a group, the adjusted rate ratio scarcely changed from the unadjusted value of 1.07 (data not shown). Stratification by years smoked suggested an eVect modification: in this study lung cancer mortality was much greater among subjects randomly allocated to the screening group who had smoked for fewer than 30 years than among subjects in the usual care group who had smoked for fewer than 30 years (table 2) . The eVect of screening did not diVer at other levels of years smoked. There also was a suggestion of eVect modification by exposure to non-tobacco carcinogens, with a benefit of screening suggested only for subjects exposed to non-tobacco carcinogens, and perhaps a deleterious eVect for subjects not exposed (table 2) . The stratum-specific rate ratios, however, did not diVer twofold. Adjustment for the four potential confounders did not change stratumspecific odds ratios meaningfully (data not shown). In no analyses was the assumption of proportional hazards rejected.
Discussion
In this reanalysis of the Mayo Lung Project data, adjustment for age at randomisation, cigarette smoking patterns, exposure to nontobacco lung carcinogens, and previous lung illness did not change the null relation between lung cancer mortality and frequent chest x ray examination and sputum cytology. Number of years smoked might have influenced the relation-the rate ratio for subjects who smoked for fewer than 30 years was 2.4, whereas the rate ratio for subjects who smoked for 30 to 39 years or 40 or more years was 1.0 in both instances. We suspect that such eVect modification occurred by chance. Although subjects who smoke for a short amount of time may be, on average, younger than other smokers, young age cannot explain the increase in risk, as the risk was not raised among the younger subjects in this trial. Proponents of lung cancer screening often suggest that the lack of statistical power to detect a small yet meaningful reduction in lung cancer mortality (the Mayo Lung Project was designed to have 95% power to detect a 50% reduction in mortality, 9 yet the final study size ultimately provided only 50% power to detect a more realistic 20% reduction 3 ) and contamination of the unscreened group (about half the unscreened group received an annual chest x ray examination during the study 6 ) explain in part the null result observed in the Mayo Lung Project. Strauss et al 2 suggest that because five year survival was greater and fatality lower in the screened group, screening actually may be eYcacious. Although lead time, length time, and overdiagnosis biases have been suggested as explanations for conflicting survival and mortality results, Strauss et al 2 argue that such biases may not explain the discrepancy. The authors suggest that population heterogeneity instead might have been responsible. We have shown, however, that adjustment for four major lung cancer factors did not alter the results. Of course, the eVect of unknown, or unmeasured factors (perhaps genetic susceptibility as Strauss et al 2 suggest) might have been responsible. One would fully expect, however, that such factors were balanced by the randomisation, as were the factors that we examined in this paper.
If the follow up time in the Mayo Lung Project was too short for unresectable tumours in unscreened subjects to become clinically evident, additional follow up time would probably aVect the mortality results. 3 We currently are obtaining mortality information on the Mayo Lung Project participants alive in June 1983. These additional data will address another controversy that remains about the Mayo Lung Project. 
